Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06370754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06370754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 30, 2024
Completion date
April 30, 2027
Enrollment
117 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer